open access

Vol 86, No 4 (2018)
ORIGINAL PAPERS
Published online: 2018-08-15
Submitted: 2018-05-03
Accepted: 2018-08-06
Get Citation

Study of pulmonary function tests in Type 2 Diabetes Mellitus and their correlation with glycemic control and systemic inflammation

Ilavarasi Vanidassane, Rupali Malik, Neelima Jain
DOI: 10.5603/ARM.a2018.0026
·
Pubmed: 30110118
·
Adv Respir Med 2018;86(4):172-178.

open access

Vol 86, No 4 (2018)
ORIGINAL PAPERS
Published online: 2018-08-15
Submitted: 2018-05-03
Accepted: 2018-08-06

Abstract

Introduction: Reduced lung function in diabetes has been described for long but its clinical importance is not yet clear. Also, limited literature is available regarding its association with sugar control, and its correlation with inflammatory markers. Thus, we aimed to study the pulmonary function test abnormalities and systemic inflammation in type 2 diabetes mellitus. Material and methods: 100 patients with type 2 diabetes were divided into two groups depending on control of diabetes (group A–HbA1C ≤ 7% and group B-HbA1C > 7%). All the subjects selected underwent detailed evaluation including testing for HbA1C, HsCRP (high-sensitivity C-reactive protein), serum ferritin and serum fibrinogen, along with pulmonary function testing. Results: Percentage predicted FVC (forced vital capacity), FEV1 (forced expiratory volume in 1 second) and SVC (slow vital capacity) were significantly reduced, while mean values of inflammatory markers [fibrinogen (p < 0.001) and hsCRP (p < 0.002)] were significantly higher in uncontrolled diabetes group. There was a significant negative correlation between FEV1 (r = –0.739, p < 0.001), FVC (r = –0.370, p < 0.001), SVC (r = –0.635, p < 0.001) with HbA1C. HbA1C had a positive correlation with hsCRP (r = –0.308, p < 0.002) and fibrinogen (r = 0.388, p < 0.001). Conclusion: Pulmonary functions were decreased and inflammatory markers like hsCRP, fibrinogen, and ferritin significantly increased in uncontrolled diabetics. Also, a potential association was seen between higher values of inflammatory markers like hsCRP and fibrinogen and decrease in lung function. This information, requiring confirmation with larger multicentre studies, remains important because of potential epidemiological, clinical and therapeutic implications.

Abstract

Introduction: Reduced lung function in diabetes has been described for long but its clinical importance is not yet clear. Also, limited literature is available regarding its association with sugar control, and its correlation with inflammatory markers. Thus, we aimed to study the pulmonary function test abnormalities and systemic inflammation in type 2 diabetes mellitus. Material and methods: 100 patients with type 2 diabetes were divided into two groups depending on control of diabetes (group A–HbA1C ≤ 7% and group B-HbA1C > 7%). All the subjects selected underwent detailed evaluation including testing for HbA1C, HsCRP (high-sensitivity C-reactive protein), serum ferritin and serum fibrinogen, along with pulmonary function testing. Results: Percentage predicted FVC (forced vital capacity), FEV1 (forced expiratory volume in 1 second) and SVC (slow vital capacity) were significantly reduced, while mean values of inflammatory markers [fibrinogen (p < 0.001) and hsCRP (p < 0.002)] were significantly higher in uncontrolled diabetes group. There was a significant negative correlation between FEV1 (r = –0.739, p < 0.001), FVC (r = –0.370, p < 0.001), SVC (r = –0.635, p < 0.001) with HbA1C. HbA1C had a positive correlation with hsCRP (r = –0.308, p < 0.002) and fibrinogen (r = 0.388, p < 0.001). Conclusion: Pulmonary functions were decreased and inflammatory markers like hsCRP, fibrinogen, and ferritin significantly increased in uncontrolled diabetics. Also, a potential association was seen between higher values of inflammatory markers like hsCRP and fibrinogen and decrease in lung function. This information, requiring confirmation with larger multicentre studies, remains important because of potential epidemiological, clinical and therapeutic implications.

Get Citation

Keywords

diabetes, pulmonary function tests, inflammatory markers

Supplementary Files (1)
Supplementary File
Download
11KB
About this article
Title

Study of pulmonary function tests in Type 2 Diabetes Mellitus and their correlation with glycemic control and systemic inflammation

Journal

Advances in Respiratory Medicine

Issue

Vol 86, No 4 (2018)

Pages

172-178

Published online

2018-08-15

DOI

10.5603/ARM.a2018.0026

Pubmed

30110118

Bibliographic record

Adv Respir Med 2018;86(4):172-178.

Keywords

diabetes
pulmonary function tests
inflammatory markers

Authors

Ilavarasi Vanidassane
Rupali Malik
Neelima Jain

References (20)
  1. Sandler M. Is the lung a 'target organ' in diabetes mellitus? Arch Intern Med. 1990; 150(7): 1385–1388.
  2. Kaparianos A, Argyropoulou E, Sampsonas F, et al. Pulmonary complications in diabetes mellitus. Chron Respir Dis. 2008; 5(2): 101–108.
  3. Lim SY, Rhee EJ, Sung KC. Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. J Korean Med Sci. 2010; 25(10): 1480–1486.
  4. Sampol G, Lecube A. Type 2 diabetes and the lung: a bidirectional relationship. Endocrinol Nutr. 2012; 59(2): 95–97.
  5. Dennis RJ, Maldonado D, Rojas MX, et al. Inadequate glucose control in type 2 diabetes is associated with impaired lung function and systemic inflammation: a cross-sectional study. BMC Pulm Med. 2010; 10: 38.
  6. G SK. Deterioration of pulmonary functions in type 2 diabetes mellitus. IOSR Journal of Pharmacy and Biological Sciences. 2012; 1(1): 39–43.
  7. Verma S, Goni M, Kudyar RP. Assesment of pulmonary function tests in patients with diabetes mellitus. JK Science. 2009; 11(2): 71–74.
  8. Kanyakumari DH, Natraj SM, et al. correlation of duration of diabetes and pulmonary function test in type 2 diabetes mellitus patients. Int. J. Biol Med Res. 2011; 28(2): 89–92.
  9. Shah SH, Sonawane P, Nahar P, et al. Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India. 2013; 30(2): 108–112.
  10. Dharwadkar AR, Dharwadkar AA, Banu G, et al. Reduction in lung functions in type-2 diabetes in Indian population: correlation with glycemic status. Indian J Physiol Pharmacol. 2011; 55(2): 170–175.
  11. Walter RE, Beiser A, Givelber RJ, et al. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med. 2003; 167(6): 911–916.
  12. Davis WA, Knuiman M, Kendall P, et al. Fremantle Diabetes Study. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004; 27(3): 752–757.
  13. Irfan M, Jabbar A, Haque AS, et al. Pulmonary functions in patients with diabetes mellitus. Lung India. 2011; 28(2): 89–92.
  14. Weynand B, Jonckheere A, Frans A, et al. Diabetes mellitus induces a thickening of the pulmonary basal lamina. Respiration. 1999; 66(1): 14–19.
  15. Ljubić S, Metelko Z, Car N, et al. Reduction of diffusion capacity for carbon monoxide in diabetic patients. Chest. 1998; 114(4): 1033–1035.
  16. Goldman MD. Clinical application of forced oscillation. Pulm Pharmacol Ther. 2001; 14(5): 341–350.
  17. Sandler M, Bunn AE, Stewart RI. Cross-section study of pulmonary function in patients with insulin-dependent diabetes mellitus. Am Rev Respir Dis. 1987; 135(1): 223–229.
  18. Hsia CCW, Raskin P. Lung function changes related to diabetes mellitus. Diabetes Technol Ther. 2007; 9 Suppl 1: S73–S82.
  19. Ehrilch SF, Quesenberry CP, Van Den Eden SK, et al. Patients dignosed with diabetes are at increased risk for asthama, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010; 33(1): 55–60.
  20. Pitsavos C, Tampourlou M, Panagiotakos DB, et al. Association Between Low-Grade Systemic Inflammation and Type 2 Diabetes Mellitus Among Men and Women from the ATTICA Study. Rev Diabet Stud. 2007; 4(2): 98–104.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl